Last reviewed · How we verify
Combigan Ophthalmic Solutiom
Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Combigan Ophthalmic Solutiom |
|---|---|
| Sponsor | Genovate Biotechnology Co., Ltd., |
| Drug class | Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist |
| Target | Alpha-2 adrenergic receptors and beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine tartrate, the alpha-2 agonist component, selectively stimulates alpha-2 adrenergic receptors to reduce aqueous humor production and enhance uveoscleral outflow. Timolol maleate, the non-selective beta-blocker component, decreases aqueous humor production through inhibition of beta-adrenergic receptors. Together, these complementary mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Ocular pruritus
- Blurred vision
- Dry eye
- Allergic conjunctivitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combigan Ophthalmic Solutiom CI brief — competitive landscape report
- Combigan Ophthalmic Solutiom updates RSS · CI watch RSS
- Genovate Biotechnology Co., Ltd., portfolio CI